Promises, Pitfalls, and Paths Forward for the Pediatric Research Equity Act

To ensure children have access to safe, effective, evidence-based medications, effective policy changes are necessary. The FDA should use its new authority to ensure the timely completion of required pediatric studies and enhance public transparency by improving mechanisms to track PREA-mandated research.

Corresponding Author: Alexa Pagano, MD, Children’s Mercy Hospital, 2401 Gillham Rd, Kansas City, MO 64108 (alpagano@cmh.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.